# Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy

> **NCT02577393** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 83 (estimated)

## Conditions studied

- Lung Neoplasms
- Esophagitis
- Prevention & Control
- Epigallocatechin Gallate

## Interventions

- **DRUG:** EGCG
- **DRUG:** EGCG
- **DRUG:** mLDG

## Key facts

- **NCT ID:** NCT02577393
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2022-06
- **Final completion:** 2022-08
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577393, "Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02577393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*